Elranatamab
- Generic Name
- Elranatamab
- Brand Names
- Elrexfio
- Drug Type
- Biotech
- CAS Number
- 2408850-14-4
- Unique Ingredient Identifier
- L0HR9A577V
- Background
Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure. The resulting 4-chain bispecific antibody is covalently linked via five inter-chain disulfide bonds. On August 14, 2023, the FDA granted accelerated approval to elranatamab for the treatment of multiple myeloma.
- Indication
Elranatamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).
- Associated Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
- Conditions
- BCMAElranatamabRelapsed Multiple MyelomaRefractory Multiple MyelomaMultiple MyelomaBispecificBCMA-CD3 BispecificMyelomaPF-06863135MagnetisMM-8
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 39
- Registration Number
- NCT05228470
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Peking University Third Hospital, Beijing, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT05090566
- Locations
- 🇺🇸
Banner Gateway Medical Center, Gilbert, Arizona, United States
🇺🇸Banner Gateway Medical Pavilion, Gilbert, Arizona, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 759
- Registration Number
- NCT05020236
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇫🇮Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus), Helsinki, Finland
🇫🇷Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren, Limoges, Limousin, France
A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT05014412
- Locations
- 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Poudre Valley Hospital, Fort Collins, Colorado, United States
MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4
- Registration Number
- NCT04798586
- Locations
- 🇯🇵
Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan
🇯🇵Nagoya City University Hospital, Nagoya, Aichi, Japan
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 188
- Registration Number
- NCT04649359
- Locations
- 🇪🇸
Clinica Universitaria de Navarra, Madrid, Spain
🇯🇵Gunma University Hospital, Maebashi, Gunma, Japan
🇺🇸University of Iowa - Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.